Photo of David Pook

View Scopus Profile

David Pook

Dr

20082024
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Dr David Pook is a Medical Oncologist working with the Prostate Cancer Research Program in the Department of Anatomy and Developmental Biology. Dr Pook's research work is directed towards developing a better understanding of castrate resistant prostate cancer. He is also a lead investigator in the VCA funded CAPTIV prostate cancer research program.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2024

A Phase 2, Randomized, Non-Comparative, Open-Label Study of NKTR-214 in Combination with Nivolumab and of Chemotherapy in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients with Low PD-L1 Expression

Pook, D.

24/06/19 → 23/06/24

Project: Research

A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïvepts with bone predominant metastatic castration-resistant prostate cancer (CRPC)

Pook, D.

20/06/19 → 19/06/24

Project: Research

A Phase Iii, Multicenter, Randomized Study Of Atezolizumab (Anti−Pdl1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castrationresistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen

Pook, D.

20/05/19 → 19/05/24

Project: Research

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative To Placebo Plus Abiraterone Plus Prednisone/Prednisolone In Adult Male Patients With Asymptomatic Or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Pook, D.

6/05/19 → 5/05/24

Project: Research

A Phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy

Pook, D.

30/04/19 → 29/04/24

Project: Research

Research Output 2008 2019

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G., McCaffrey, J., McDermott, R., McJannett, M., North, S. A., Parnis, F., Parulekar, W., Pook, D. W. & 13 othersReaume, M. N., Sandhu, S. K., Tan, A., Tan, T. H., Thomson, A., Tu, E., Vera-Badillo, F., Williams, S. G., Yip, S., Zhang, A. Y., Zielinski, R. R., Sweeney, C. J. & for the ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, 2 Jun 2019, (Accepted/In press) In : New England Journal of Medicine. 11 p.

Research output: Contribution to journal › Article › Research › peer-review

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer

Kwan, E. M., Fettke, H., Docanto, M. M., To, S. Q., Bukczynska, P., Mant, A., Pook, D., Ng, N., Graham, L. J. K., Mangiola, S., Segelov, E., Mahon, K., Davis, I. D., Parente, P., Pezaro, C., Todenhöfer, T., Horvath, L. G. & Azad, A. A., 15 May 2019, (Accepted/In press) In : European Urology Focus. 8 p.

Research output: Contribution to journal › Article › Research › peer-review

Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study

Ha, F. J., Spain, L., Dowling, A., Kwan, E. M., Pezaro, C., Day, D., Chia, P. L., Tran, B., Pook, D. & Weickhardt, A. J., 30 Jan 2019, (Accepted/In press) In : Asia-Pacific Journal of Clinical Oncology. 6 p.

Research output: Contribution to journal › Article › Research › peer-review

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC)

Kwan, E. M., To, S. Q. G., Fettke, H. C., Docanto, M., Bukczynska, P., Mant, A. M., Pook, D. W., Ng, N., Graham, L. J. K., Segelov, E., Mahon, K. L., Davis, I., Parente, P., Pezaro, C., Horvath, L. G. & Azad, A., 1 Mar 2019, In : Journal of Clinical Oncology. 37, 7 Suppl, p. 188 1 p.

Research output: Contribution to journal › Meeting Abstract › Other › peer-review

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

Lawrence, M. G., Obinata, D., Sandhu, S., Selth, L. A., Wong, S. Q., Porter, L. H., Lister, N., Pook, D., Pezaro, C. J., Goode, D. L., Rebello, R. J., Clark, A. K., Papargiris, M., Van Gramberg, J., Hanson, A. R., Banks, P., Wang, H., Niranjan, B., Keerthikumar, S., Hedwards, S. & 32 othersHuglo, A., Yang, R., Henzler, C., Li, Y., Lopez-Campos, F., Castro, E., Toivanen, R., Azad, A., Bolton, D., Goad, J., Grummet, J., Harewood, L., Kourambas, J., Lawrentschuk, N., Moon, D., Murphy, D. G., Sengupta, S., Snow, R., Thorne, H., Mitchell, C., Pedersen, J., Clouston, D., Norden, S., Ryan, A., Dehm, S. M., Tilley, W. D., Pearson, R. B., Hannan, R. D., Frydenberg, M., Furic, L., Taylor, R. A. & Risbridger, G. P., 1 Nov 2018, In : European Urology. 74, 5, p. 562-572 11 p.

Research output: Contribution to journal › Article › Research › peer-review